Overview

Study of Ixekizumab in Participants With Active Ankylosing Spondylitis (AS)

Status:
Withdrawn
Trial end date:
2018-04-01
Target enrollment:
Participant gender:
Summary
This study will assess the safety and efficacy of ixekizumab (LY2439821) compared to placebo in participants with active AS.
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Adalimumab
Ixekizumab